Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better
Aim: Recently, three randomized controlled trials evaluated the addition of docetaxel to ADT in advanced hormone-sensitive prostate cancer (aHSPC). Interestingly, all trials showed a trend towards improved OS in the subgroup of patients with Gleason <8 tumors. We herein performed a meta-analysis...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Turkiye Klinikleri
2019-08-01
|
| Series: | Journal of Oncological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336418300967 |
| _version_ | 1828022952063401984 |
|---|---|
| author | Omer Dizdar Deniz Can Guven Gurkan Guner Mustafa Erman Mutlu Hayran |
| author_facet | Omer Dizdar Deniz Can Guven Gurkan Guner Mustafa Erman Mutlu Hayran |
| author_sort | Omer Dizdar |
| collection | DOAJ |
| description | Aim: Recently, three randomized controlled trials evaluated the addition of docetaxel to ADT in advanced hormone-sensitive prostate cancer (aHSPC). Interestingly, all trials showed a trend towards improved OS in the subgroup of patients with Gleason <8 tumors. We herein performed a meta-analysis of these trials to assess the OS benefit of docetaxel in different Gleason score groups (<8 vs ≥8). Material and Method: We searched the Pubmed and Medline databases and ASCO conference proceedings (through February 1st 2018) for relevant trials. For each study, median OS values and hazard ratios (HR) with 95% confidence intervals (CI) collected across different Gleason score groups. We combined the HRs from each of the three eligible trials in the meta-analysis using the random-effect model. Results: Three eligible studies were included in the analyses (CHAARTED, GETUG-AFU-15, and STAMPEDE). In the meta-analysis of three studies, docetaxel-based chemotherapy plus ADT was associated with improved OS [HR: 0.74; 95% CI: 0.62-0.87; p<0.001]. Among patients with tumor Gleason score <8, addition of docetaxel to ADT significantly improved overall survival [HR: 0.66, 95% CI: 0.52–0.85, p=0.001]. Although there was a trend towards improved OS with docetaxel in patients with Gleason score of ≥8, the magnitude of risk reduction was lower and did not achieve statistical significance [HR: 0.81, 95% CI: 0.64–1.02, p=0.066]. Conclusion: In this meta-analysis, OS benefit with the addition of docetaxel to ADT was more prominent in Gleason score <8 tumors. We propose that Gleason score can be a useful criteria for treatment selection in patients with aHSPC. Keywords: Hormone-sensitive, prostate cancer, docetaxel, gleason score |
| first_indexed | 2024-04-10T12:18:43Z |
| format | Article |
| id | doaj.art-38b91bdbfa5842a3918ad42b195e3c97 |
| institution | Directory Open Access Journal |
| issn | 2452-3364 |
| language | English |
| last_indexed | 2024-04-10T12:18:43Z |
| publishDate | 2019-08-01 |
| publisher | Turkiye Klinikleri |
| record_format | Article |
| series | Journal of Oncological Sciences |
| spelling | doaj.art-38b91bdbfa5842a3918ad42b195e3c972023-02-15T16:15:33ZengTurkiye KlinikleriJournal of Oncological Sciences2452-33642019-08-01524548Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the betterOmer Dizdar0Deniz Can Guven1Gurkan Guner2Mustafa Erman3Mutlu Hayran4Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey; Corresponding author. Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey.Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDepartment of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDepartment of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyAim: Recently, three randomized controlled trials evaluated the addition of docetaxel to ADT in advanced hormone-sensitive prostate cancer (aHSPC). Interestingly, all trials showed a trend towards improved OS in the subgroup of patients with Gleason <8 tumors. We herein performed a meta-analysis of these trials to assess the OS benefit of docetaxel in different Gleason score groups (<8 vs ≥8). Material and Method: We searched the Pubmed and Medline databases and ASCO conference proceedings (through February 1st 2018) for relevant trials. For each study, median OS values and hazard ratios (HR) with 95% confidence intervals (CI) collected across different Gleason score groups. We combined the HRs from each of the three eligible trials in the meta-analysis using the random-effect model. Results: Three eligible studies were included in the analyses (CHAARTED, GETUG-AFU-15, and STAMPEDE). In the meta-analysis of three studies, docetaxel-based chemotherapy plus ADT was associated with improved OS [HR: 0.74; 95% CI: 0.62-0.87; p<0.001]. Among patients with tumor Gleason score <8, addition of docetaxel to ADT significantly improved overall survival [HR: 0.66, 95% CI: 0.52–0.85, p=0.001]. Although there was a trend towards improved OS with docetaxel in patients with Gleason score of ≥8, the magnitude of risk reduction was lower and did not achieve statistical significance [HR: 0.81, 95% CI: 0.64–1.02, p=0.066]. Conclusion: In this meta-analysis, OS benefit with the addition of docetaxel to ADT was more prominent in Gleason score <8 tumors. We propose that Gleason score can be a useful criteria for treatment selection in patients with aHSPC. Keywords: Hormone-sensitive, prostate cancer, docetaxel, gleason scorehttp://www.sciencedirect.com/science/article/pii/S2452336418300967 |
| spellingShingle | Omer Dizdar Deniz Can Guven Gurkan Guner Mustafa Erman Mutlu Hayran Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better Journal of Oncological Sciences |
| title | Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better |
| title_full | Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better |
| title_fullStr | Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better |
| title_full_unstemmed | Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better |
| title_short | Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better |
| title_sort | gleason score and docetaxel response in advanced hormone sensitive prostate cancer the lower the better |
| url | http://www.sciencedirect.com/science/article/pii/S2452336418300967 |
| work_keys_str_mv | AT omerdizdar gleasonscoreanddocetaxelresponseinadvancedhormonesensitiveprostatecancerthelowerthebetter AT denizcanguven gleasonscoreanddocetaxelresponseinadvancedhormonesensitiveprostatecancerthelowerthebetter AT gurkanguner gleasonscoreanddocetaxelresponseinadvancedhormonesensitiveprostatecancerthelowerthebetter AT mustafaerman gleasonscoreanddocetaxelresponseinadvancedhormonesensitiveprostatecancerthelowerthebetter AT mutluhayran gleasonscoreanddocetaxelresponseinadvancedhormonesensitiveprostatecancerthelowerthebetter |